- £67.71bn
- £81.07bn
- £30.33bn
- 86
- 47
- 80
- 85
REG - GSK PLC - Japan Filing Acceptance: Blenrep Multiple Myeloma
AnnouncementREG - GSK PLC - China Breakthrough Therapy Designation for Blenrep
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Positive mRNA flu vaccine Phase II headline data
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Change of Registered Office
AnnouncementREG - GSK PLC - Update on phase I/II therapeutic HSV vaccine trial
AnnouncementREG - GSK PLC - Depemokimab late-breaking data presented at ERS
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Positive Phase III results for Nucala in COPD
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - EMA approval on Arexvy for 50-59 at risk
AnnouncementREG - GSK PLC - Nucala approved in Japan for use in CRSwNP
AnnouncementREG - GSK PLC - SENKU Designation for Bepirovirsen in Japan
AnnouncementREG - GSK PLC - Statement: Zantac (ranitidine) litigation
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - B7-H3 ADC US FDA Breakthrough Therapy Designation
Announcement